| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $56.5M | -3.0% | +40.1% |
| SG&A Expense | $27.5M | +25.1% | +189.4% |
| Operating Income | -$83.9M | -4.7% | -68.5% |
| Net Income | -$80.3M | -4.9% | -72.2% |
| EPS (Basic) | -$1.26 | -5.0% | -48.2% |
| EPS (Diluted) | -$1.26 | -5.0% | -48.2% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $57.8M | +17.6% | +112.0% |
| Short-term Investments | $439.6M | -13.4% | +34.8% |
| Current Assets | $511.3M | -10.5% | +40.4% |
| Total Assets | $517.5M | -10.5% | +40.4% |
| Current Liabilities | $41.9M | +24.8% | +58.3% |
| Long-term Debt |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$171.1M | — | — |
| Capital Expenditures | $528K | — | — |
| Investing Cash Flow | $113.6M | — | — |
| Financing Cash Flow | $22.6M | — | — |
| Free Cash Flow | -$171.6M | — | — |
| $74.6M |
| +0.2% |
| +47.9% |
| Total Liabilities | $118.6M | +7.6% | +49.2% |
| Stockholders' Equity | $398.9M | -14.8% | +38.0% |